A shelf registration statement relating to the securities to be issued in the Public
Offering is on file with and has been declared effective by the Securities and Exchange Commission (the SEC). The Public Offering may be made only by means of a prospectus and a related prospectus supplement, copies of which may be
obtained, when available, from any of the following investment banks: Morgan Stanley & Co. LLCAttn: Prospectus Department180 Varick Street, 2nd FloorNew York, NY 10014; Wells Fargo Securities, LLC, Attention: Equity
Syndicate at 375 Park Avenue, New York, NY 10152-4077, or by calling (800)
326-5897,
or by email: cmclientsupport@wellsfargo.com; Goldman Sachs & Co. LLC, Prospectus Department, 200 West Street, New
York, NY 10282, telephone:
1-866-471-2526,
facsimile:
212-902-9316
or by emailing
Prospectus-ny@ny.email.gs.com.;
J.P. Morgan, Attention: Prospectus Department, c/o Broadridge
Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by calling toll-free at (866)
803-9204;
or Keefe, Bruyette & Woods, Inc., Attn: Capital Markets, 787 Seventh Avenue, 4th
Floor, New York, NY 10019, telephone:
1-800-966-1559.
The preliminary prospectus supplement, dated August 6, 2018, and accompanying prospectus, dated May 14, 2018, each of which has
been filed with the SEC, contain a description of these matters and other important information about the Company and should be read carefully before investing. Investors are advised to carefully consider the investment objectives, risks and
charges and expenses of the Company before investing.
The securities to be sold in the Private Placements have not been registered
under the Securities Act, or any applicable state securities laws. The securities to be issued in the Private Placements may not be offered or sold in the United States absent registration or an applicable exemption from the registration
requirements of the Securities Act.
About TriplePoint Venture Growth BDC Corp.
The Company serves as the primary financing source for the venture growth stage business segment of TriplePoint Capital LLC, the leading
global provider of financing across all stages of development to technology, life sciences and other high growth companies backed by a select group of venture capital firms. The Companys investment objective is to maximize its total
return to stockholders primarily in the form of current income and, to a lesser extent, capital appreciation by primarily lending with warrants to venture growth stage companies. The Company is an externally managed,
closed-end,
non-diversified
management investment company that has elected to be regulated as a business development company under the Investment Company Act of 1940, as
amended.
2